Group 1 - The core viewpoint of the article highlights the significant decline in the stock price of Furu Medical Technology (01696), which dropped nearly 5% after a previous decline of over 13% [1] - Furu Medical Technology reported a revenue of $165 million for the first half of 2025, representing a year-on-year decrease of 1.9% [1] - The net profit attributable to the parent company was $6.426 million, down 41.3% year-on-year, primarily due to challenging market conditions in North America, including high interest rates and weak consumer demand [1] Group 2 - The company indicated that revenue recognition was slightly delayed due to transportation restrictions caused by regional tensions in June [1] - Excluding the adverse factors in the North American market, Furu Medical Technology achieved a 7.1% growth in international markets compared to the same period in 2024 [1] - According to Shenwan Hongyuan, the decline in revenue in the North American market significantly impacted overall performance, while the international market benefited from a direct sales office layout [1] Group 3 - The company is recognized as a leading player in the energy source medical aesthetic device sector, leveraging its direct sales network to strengthen its advantages in the Asia-Pacific region [1] - The injection filler business is expected to open a second growth curve for the company [1] - Despite short-term challenges in North America, the long-term growth logic remains intact, with expectations for a rebound in performance in the second half of the year driven by the launch of Daxifei and the expansion of the combined treatment ecosystem [1]
港股异动 | 复锐医疗科技(01696)再跌近5% 北美市场承压拖累整体业绩 公司上半年纯利同比降四成